ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zanidatamab

Also written as “Zanidatamab” and “ZW25 (Zanidatamab)”.

Its studies are mostly in Breast Neoplasms · Biliary Tract Neoplasms · Stomach Neoplasms, led by 2 companies.

Drug pageZanidatamab: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 5, 202111 company-led studies, 5 open or runningLicense: Zymeworks → Jazz, Oct 2022Next primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticalsits history only105 open or runningphase 3since Nov 5, 2021Aug 23, 2016Dec 31, 2026phase 2 · NCT06695845
BeOne Medicines10 open or runningphase 3since Nov 14, 2019Nov 14, 2019none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland and ALX Oncology.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of BeOne Medicines only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2018BeiGene (now BeOne) licensed it from ZymeworksLicenseAsia (except Japan), Australia and New Zealand · announced · Zymeworks and BeiGene (8-K exhibit)
  2. Jun 9, 2019Named zanidatamabINNProposed as its International Nonproprietary Name in WHO's List 121
  3. Nov 14, 2019First study: phase 3 study in Advanced MalignanciesFirst studyNCT04164199 · 404 enrolled · United States, Australia, China and more
  4. Oct 19, 2022Jazz licensed it from ZymeworksLicenseEverywhere outside the Asia-Pacific territories licensed to BeiGene · announced · Jazz and Zymeworks (8-K exhibit)

TargetBeta

ERBB2 →read by rule
“An engineered immunoglobulin G1 (IgG1) bi-specific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

The one study BeOne Medicines leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04164199Advanced Malignancies · United States, Australia, China and more3CompletedMay 23, 2026404

How it is read

Names in the registry

  • “Zanidatamab”, 7 entries
  • “ZW25 (Zanidatamab)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.